Melhoria de procedimentos internos no laboratório do Instituto dos Vinhos do Douro e do Porto, I.P.

Este relatório foi elaborado no âmbito do estágio curricular realizado na Direção de Serviços Técnicos e de Certificação do Instituto dos Vinhos do Douro e do Porto, I.P. Teve como principal objetivo apresentar propostas de alteração de procedimentos internos do laboratório do Instituto dos Vinhos do Douro e do Porto, I.P., no sentido de reduzir o tempo de resposta às solicitações, procurando uma melhor rentabilização tanto de equipamentos como de recursos humanos. Para atingir tal objetivo, foi elaborado o diagnóstico da situação, com base na informação recolhida na Direção de Serviços Técnicos e de Certificação, incluindo os dados fornecidos pelo software GLAB que dá apoio às operações realizadas no laboratório do Instituto dos Vinhos do Douro e do Porto. Além disso, foi efetuado o acompanhamento do circuito das amostras de produtos vínicos desde a sua receção, à análise nos setores do laboratório e posterior validação dos resultados. Dado que o estudo da entrada de amostras no setor Análise Mineral foi maioritariamente inconclusivo, apurou-se o custo por análise na determinação do chumbo e, ainda, foi realizada uma simulação determinar a despesa necessária para reduzir o número de amostras analisadas de cada vez que se liga o equipamento. Foi ainda comparado o custo da determinação do parâmetro furfural, análise que tanto pode ser realizada no setor Cromatografia Gasosa como no setor Cromatografia Líquida. Para isso, foram utlizados vários testes estatísticos. Com base na avaliação efetuada foram identificadas e propostas as seguintes oportunidades de melhoria: - Automação de uma das atividades realizadas no setor Físico-Química I, atividade esta necessária à preparação das análises; - Contrabalançar a sazonalidade verificada na receção de amostras dos clientes com as amostras provenientes da Direção de Serviços de Fiscalização e Controlo; - Inserção de algumas variáveis no software GLAB. É de realçar que a proposta referente à automação de uma das atividades realizadas no setor Físico-Química foi implementada pelo IVDP. Foram, também, identificadas propostas de futuras investigações.

Anais do Parlamento Brasileiro : índice de janeiro a fevereiro de 1843 : Tomo I

Câmara dos Srs. Deputados . Primeiro(1º) Ano da Quinta (5ª) Legislatura.

História da arte portuguesa medieval : arte gótica : arquitectura civil : o paço medieval : I parte

Académico - Licenciaturas

A influência do treino e de um protocolo preventivo no complexo articular do ombro em voleibolistas da I Divisão

Projeto de Graduação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Licenciada em Fisioterapia

Saúde da criança I

Módulo 05 do Curso de Especialização em Saúde da Família da UNA-SUS/UFMA, com apresentação visual trabalhada para atender aos alunos participantes do programa Mais Médicos. Apresenta o contexto de surgimento e implantação das políticas de saúde, a participação, estratégias e ações da equipe de saúde da família na atenção a saúde da criança.

Saúde do adulto I

Backup Moodle do Módulo 7 do Curso de Especialização em Saúde da Família, produzido pela UNA-SUS/UFMA, com apresentação visual trabalhada para atender aos alunos participantes do programa Mais Médicos. Apresenta as interfaces políticas e instrucionais que tratam a temática dos principais problemas de saúde voltados ao adulto, mais precisamente, a saúde do homem. Também aborda o planejamento e organização das ações de saúde e os principais agravos relacionados à saúde do adulto.

Implantação de um programa de intervenções não medicamentosas para controle e tratamento da hipertensão no PSF Pontello I _ Pitangui MG

O Programa Saúde da Família (PSF) surge no Brasil como uma estratégia de reorientação do modelo assistencial a partir da atenção básica, em conformidade com os princípios do Sistema Único de Saúde. O PSF se apresenta como uma nova maneira de trabalhar a saúde, tendo a família como centro de atenção e não somente o indivíduo doente, introduzindo nova visão no processo de intervenção em saúde na medida em que não espera a população chegar para ser atendida, pois age preventivamente sobre ela a partir de um novo modelo de atenção. O PSF Pontello I pertence à cidade de Pitangui e atende a uma população de aproximadamente 25.339 habitantes. Ao realizar diagnóstico situacional da área de abrangência do PSF Pontello I, foram identificados diversos problemas como o aumento da violência e o pouco acesso da população a atividades de lazer. Entretanto, o problema de maior relevância está relacionado com a alta incidência de portadores de Hipertensão Arterial Sistêmica (HAS) o que segundo a Sociedade Brasileira de Cardiologia não se difere os dados do município aos do Brasil. A HAS é um grave problema de saúde pública, sendo considerado um dos principais fatores de risco para as doenças cardiovasculares. Segundo a Sociedade Brasileira de Cardiologia e Sociedade Brasileira de Hipertensão, o seu controle depende de medidas farmacológicas e não farmacológicas como a redução do consumo de álcool, o controle da obesidade, a dieta equilibrada, a prática regular de atividade física e a cessação do tabaco. A adesão a esses hábitos de vida favorece a redução dos níveis pressóricos e contribui para a prevenção de complicações. Assim, foi elaborada uma proposta de intervenção com o objetivo de implantar um programa de ações que favoreçam a adesão ao tratamento e controle da Hipertensão Arterial Sistêmica de usuários acompanhados pelo enfermeiro e agentes comunitários de saúde do PSF Pontello I no município de Pitangui/MG. Com o desenvolvimento deste trabalho, esperam-se melhorias na qualidade da assistência ao portador de HAS atendido pela equipe do PSF Pontello I o que acarretará em melhora na qualidade de vida dos pacientes.

An Isoflavone From Dipteryx Alata Vogel Is Active Against The In Vitro Neuromuscular Paralysis Of Bothrops Jararacussu Snake Venom And Bothropstoxin I, And Prevents Venom-induced Myonecrosis.

Snakebite is a neglected disease and serious health problem in Brazil, with most bites being caused by snakes of the genus Bothrops. Although serum therapy is the primary treatment for systemic envenomation, it is generally ineffective in neutralizing the local effects of these venoms. In this work, we examined the ability of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM), an isoflavone from Dipteryx alata, to neutralize the neurotoxicity (in mouse phrenic nerve-diaphragm preparations) and myotoxicity (assessed by light microscopy) of Bothrops jararacussu snake venom in vitro. The toxicity of TM was assessed using the Salmonella microsome assay (Ames test). Incubation with TM alone (200 μg/mL) did not alter the muscle twitch tension whereas incubation with venom (40 μg/mL) caused irreversible paralysis. Preincubation of TM (200 μg/mL) with venom attenuated the venom-induced neuromuscular blockade by 84% ± 5% (mean ± SEM; n = 4). The neuromuscular blockade caused by bothropstoxin-I (BthTX-I), the major myotoxic PLA2 of this venom, was also attenuated by TM. Histological analysis of diaphragm muscle incubated with TM showed that most fibers were preserved (only 9.2% ± 1.7% were damaged; n = 4) compared to venom alone (50.3% ± 5.4% of fibers damaged; n = 3), and preincubation of TM with venom significantly attenuated the venom-induced damage (only 17% ± 3.4% of fibers damaged; n = 3; p < 0.05 compared to venom alone). TM showed no mutagenicity in the Ames test using Salmonella strains TA98 and TA97a with (+S9) and without (-S9) metabolic activation. These findings indicate that TM is a potentially useful compound for antagonizing the neuromuscular effects (neurotoxicity and myotoxicity) of B. jararacussu venom.

Nebivolol Reduces Central Blood Pressure In Stage I Hypertensive Patients: Experimental Single Cohort Study.

Assessment of central blood pressure (BP) has grown substantially over recent years because evidence has shown that central BP is more relevant to cardiovascular outcomes than peripheral BP. Thus, different classes of antihypertensive drugs have different effects on central BP despite similar reductions in brachial BP. The aim of this study was to investigate the effect of nebivolol, a β-blocker with vasodilator properties, on the biochemical and hemodynamic parameters of hypertensive patients. Experimental single cohort study conducted in the outpatient clinic of a university hospital. Twenty-six patients were recruited. All of them underwent biochemical and hemodynamic evaluation (BP, heart rate (HR), central BP and augmentation index) before and after 3 months of using nebivolol. 88.5% of the patients were male; their mean age was 49.7 ± 9.3 years and most of them were overweight (29.6 ± 3.1 kg/m2) with large abdominal waist (102.1 ± 7.2 cm). There were significant decreases in peripheral systolic BP (P = 0.0020), diastolic BP (P = 0.0049), HR (P < 0.0001) and central BP (129.9 ± 12.3 versus 122.3 ± 10.3 mmHg; P = 0.0083) after treatment, in comparison with the baseline values. There was no statistical difference in the augmentation index or in the biochemical parameters, from before to after the treatment. Nebivolol use seems to be associated with significant reduction of central BP in stage I hypertensive patients, in addition to reductions in brachial systolic and diastolic BP.

Predictive Value Of Phase I Trials For Safety In Later Trials And Final Approved Dose: Analysis Of 61 Approved Cancer Drugs.

Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safety of new agents. We compared data from phase I and registration trials to determine whether early trials predicted later safety and final dose. We searched the U.S. Food and Drug Administration (FDA) website for drugs approved in nonpediatric cancers (January 1990-October 2012). The recommended phase II dose (R2PD) and toxicities from phase I were compared with doses and safety in later trials. In 62 of 85 (73%) matched trials, the dose from the later trial was within 20% of the RP2D. In a multivariable analysis, phase I trials of targeted agents were less predictive of the final approved dose (OR, 0.2 for adopting ± 20% of the RP2D for targeted vs. other classes; P = 0.025). Of the 530 clinically relevant toxicities in later trials, 70% (n = 374) were described in phase I. A significant relationship (P = 0.0032) between increasing the number of patients in phase I (up to 60) and the ability to describe future clinically relevant toxicities was observed. Among 28,505 patients in later trials, the death rate that was related to drug was 1.41%. In conclusion, dosing based on phase I trials was associated with a low toxicity-related death rate in later trials. The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials.

Pyrimidine-5'-nucleotidase Campinas, A New Mutation (p.r56g) In The Nt5c3 Gene Associated With Pyrimidine-5'-nucleotidase Type I Deficiency And Influence Of Gilbert's Syndrome On Clinical Expression.

Pyrimidine-5'-nucleotidase type I (P5'NI) deficiency is an autosomal recessive condition that causes nonspherocytic hemolytic anemia, characterized by marked basophilic stippling and pyrimidine nucleotide accumulation in erythrocytes. We herein present two African descendant patients, father and daughter, with P5'N deficiency, both born from first cousins. Investigation of the promoter polymorphism of the uridine diphospho glucuronosyl transferase 1A (UGT1A) gene revealed that the father was homozygous for the allele (TA7) and the daughter heterozygous (TA6/TA7). P5'NI gene (NT5C3) gene sequencing revealed a further change in homozygosity at amino acid position 56 (p.R56G), located in a highly conserved region. Both patients developed gallstones; however the father, who had undergone surgery for the removal of stones, had extremely severe intrahepatic cholestasis and, liver biopsy revealed fibrosis and siderosis grade III, leading us to believe that the homozygosity of the UGT1A polymorphism was responsible for the more severe clinical features in the father. Moreover, our results show how the clinical expression of hemolytic anemia is influenced by epistatic factors and we describe a new mutation in the P5'N gene associated with enzyme deficiency, iron overload, and severe gallstone formation. To our knowledge, this is the first description of P5'N deficiency in South Americans.

Effects Of Partial Inhibition Of Respiratory Complex I On H2o 2 Production By Isolated Brain Mitochondria In Different Respiratory States.

The aim of this work was to characterize the effects of partial inhibition of respiratory complex I by rotenone on H2O2 production by isolated rat brain mitochondria in different respiratory states. Flow cytometric analysis of membrane potential in isolated mitochondria indicated that rotenone leads to uniform respiratory inhibition when added to a suspension of mitochondria. When mitochondria were incubated in the presence of a low concentration of rotenone (10 nm) and NADH-linked substrates, oxygen consumption was reduced from 45.9 ± 1.0 to 26.4 ± 2.6 nmol O2 mg(-1) min(-1) and from 7.8 ± 0.3 to 6.3 ± 0.3 nmol O2 mg(-1) min(-1) in respiratory states 3 (ADP-stimulated respiration) and 4 (resting respiration), respectively. Under these conditions, mitochondrial H2O2 production was stimulated from 12.2 ± 1.1 to 21.0 ± 1.2 pmol H2O2 mg(-1) min(-1) and 56.5 ± 4.7 to 95.0 ± 11.1 pmol H2O2 mg(-1) min(-1) in respiratory states 3 and 4, respectively. Similar results were observed when comparing mitochondrial preparations enriched with synaptic or nonsynaptic mitochondria or when 1-methyl-4-phenylpyridinium ion (MPP(+)) was used as a respiratory complex I inhibitor. Rotenone-stimulated H2O2 production in respiratory states 3 and 4 was associated with a high reduction state of endogenous nicotinamide nucleotides. In succinate-supported mitochondrial respiration, where most of the mitochondrial H2O2 production relies on electron backflow from complex II to complex I, low rotenone concentrations inhibited H2O2 production. Rotenone had no effect on mitochondrial elimination of micromolar concentrations of H2O2. The present results support the conclusion that partial complex I inhibition may result in mitochondrial energy crisis and oxidative stress, the former being predominant under oxidative phosphorylation and the latter under resting respiration conditions.

National Institutes Of Health Consensus Development Project On Criteria For Clinical Trials In Chronic Graft-versus-host Disease: I. The 2014 Diagnosis And Staging Working Group Report.

The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.

Gut Bacteria Products Prevent Aki Induced By Ischemia-reperfusion.

Short-chain fatty acids (SCFAs) are fermentation end products produced by the intestinal microbiota and have anti-inflammatory and histone deacetylase-inhibiting properties. Recently, a dual relationship between the intestine and kidneys has been unraveled. Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process has a detrimental role. We observed that therapy with the three main SCFAs (acetate, propionate, and butyrate) improved renal dysfunction caused by injury. This protection was associated with low levels of local and systemic inflammation, oxidative cellular stress, cell infiltration/activation, and apoptosis. However, it was also associated with an increase in autophagy. Moreover, SCFAs inhibited histone deacetylase activity and modulated the expression levels of enzymes involved in chromatin modification. In vitro analyses showed that SCFAs modulated the inflammatory process, decreasing the maturation of dendritic cells and inhibiting the capacity of these cells to induce CD4(+) and CD8(+) T cell proliferation. Furthermore, SCFAs ameliorated the effects of hypoxia in kidney epithelial cells by improving mitochondrial biogenesis. Notably, mice treated with acetate-producing bacteria also had better outcomes after AKI. Thus, we demonstrate that SCFAs improve organ function and viability after an injury through modulation of the inflammatory process, most likely via epigenetic modification.